L 186/36 Official Journal of the European Union 15.7.2008 COMMISSION COMMISSION DECISION of 4 July 2008 on the financing of the storage of foot-and-mouth disease virus antigens and the formulation of vaccines reconstituted from such antigens (2008/581/EC) THE COMMISSION OF THE EUROPEAN COMMUNITIES, Having regard to the Treaty establishing the European Community, Having regard to Council Decision 90/424/EEC of 26 June 1990 on expenditure in the veterinary field ('), and in particular Article 14 thereof, Having regard to Council Directive 2003/85/EC of 29 September 2003 on Community measures for the control of foot-and-mouth disease repealing Directive 85/511/EEC and Decisions 89/531/EEC and 91/665/EEC and amending Directive 92/46[EEC (), and in particular Article 80(2) thereof, Whereas: (1)  In accordance with Council Decision 91/666/EEC of 11 December 1991 establishing Community reserves of foot-and-mouth disease vaccines (?), stocks of antigens have been established for the rapid formulation of vaccines against foot-and-mouth disease and are kept, for security reasons, at distinct designated sites on the premises of the manufacturer. (2)  Under Directive 2003/85/EC, the Commission is to ensure that Community reserves of concentrated inac- tivated antigens for the production of foot-and-mouth () OJ L 224, 18.8.1990, p. 19. Decision as last amended by Regulation (EC) No 1791/2006 (OJ L 363, 20.12.2006, p. 1). () OJ L 306, 22.11.2003, p. 1. Directive as last amended by Directive 2006/104/EC (O] L 363, 20.12.2006, p. 352). () OJ L 368, 31.12.1991, p. 21. Decision as last amended by Regu- lation (EC) No 807/2003 (O] L 122, 16.5.2003, p. 36). disease vaccines are maintained on the premises of the Community antigen and vaccine bank. (3)  For that purpose the number of doses and the diversity of serotypes and strains of antigens of foot-and-mouth disease viruses stored in the Community antigen and vaccine bank is to be decided taking into account the needs as estimated in the context of the contingency plans and the epidemiological situation, where appro- priate after consultation with the Community Reference Laboratory. (4) By Commission Decision 93/590/EC of 5 November 1993 for the purchase by the Community of foot-and- mouth disease antigens within the framework of the Community action concerning reserves of foot-and- mouth disease vaccines (%), arrangements were made for the purchase of A5 European, A22 Middle East and O1 European foot-and-mouth disease antigens. (5) By Commission Decision 97/348/EC of 23 May 1997 for the purchase by the Community of foot-and-mouth disease antigens and for the formulation, production, bottling and distribution of vaccines against foot-and- mouth disease (°), arrangements were made for the purchase of A22 Iraq, C1 and ASIA1 foot-and-mouth disease antigens. (6) By Commission Decision 2000/77/EC of 17 December 1999 for the purchase by the Community of foot-and- mouth disease antigens and for the formulation, production, bottling and distribution of vaccines against foot-and-mouth disease (°), arrangements were made for the purchase of certain doses of A Iran 96, A Iran 99, A Malaysia 97, SAT 1, SAT 2 (East African and Southern African strains) and SAT 3 foot-and-mouth disease antigens. () OJ L 280, 13.11.1993, p. 33. Decision as last amended by Decision 2000/112/EC (O] L 33, 8.2.2000, p. 21). () O] L 148, 6.6.1997, p. 27. Decision as amended by Decision 2000/112/EC. (% OJ L 30, 4.2.2000, p. 35.